Skip to main content
Frontiers in Immunology logoLink to Frontiers in Immunology
. 2025 Aug 12;16:1676745. doi: 10.3389/fimmu.2025.1676745

Correction: Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response

Zhanzhan Li 1, Yanyan Li 2, Yifu Tian 3, Na Li 1, Liangfang Shen 1, Yajie Zhao 4,5,*
PMCID: PMC12378921  PMID: 40873565

In the published article, there were errors in the Funding statement. The Funding statement is incomplete. The correct Funding statement appears below.

“This study was supported by the National Natural Science Foundation of China (LZZ: No.82003239), Hunan Provincial Natural Science Foundation of China (LZZ: No.2023JJ30907), and National key clinical specialty (SLF: 2209090720).”

The original version of this article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.


Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA

RESOURCES